-
Je něco špatně v tomto záznamu ?
Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris
M. Husakova, J. Lippert, J. Stolfa, L. Sedova, P. Arenberger, Z. Lacinova, K. Pavelka
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
- MeSH
- biologické markery metabolismus MeSH
- dospělí MeSH
- imunoradiometrická analýza MeSH
- lidé MeSH
- prolaktin metabolismus MeSH
- psoriatická artritida diagnóza MeSH
- psoriáza diagnóza MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND AND AIMS: Psoriasis vulgaris (PV) is complicated in up to 40% patients by the inflammatory joint disease psoriatic arthritis (PsA). Neither the aetiology of the arthritis nor specific laboratory markers for its disease activity have been clearly elucidated. Prolactin (PRL) acts as a cytokine with immunomodulatory functions and plays a role in skin and joint biology. The results on PRL however as a marker are unclear. The aim of this study was to confirm whether serum PRL levels reflect systemic complications of PV, like inflammatory joint disease and/or can serve as a marker of disease activity in both cases. METHODS: A total of 70 patients with PV without arthritis and 40 patients suffering from PsA were included. In all patients, we determined skin disease activity according to the PASI index and in PsA, active disease assessed as swollen or tender joints. The control group included 27 age and sex matched healthy individuals. The concentration of PRL in the serum was measured by immunoradiometric assays. RESULTS: The PRL serum levels were significantly increased in PsA patients (299.2±28.29 mIU/L) compared to PV only patients (201.4.2±11.72 mIU/L), P = 0.0003 and healthy individuals (198.2±15.31 mIU/L), P = 0.007. The serum PRL levels in PsA with active disease 336.8±42.50 (mIU/L) were higher than in PV and controls, P < 0.0001 and P = 0.002 respectively. In PV only patients, there was no correlation between PASI and PRL levels. CONCLUSION: Our results showed that PRL serum levels are a marker of active arthritis in PsA and reflects systemic complication rather than local skin activity.
Department of Dermatology Stadt Klinikum Gorlitz Gorlitz Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17004321
- 003
- CZ-PrNML
- 005
- 20170308085105.0
- 007
- ta
- 008
- 170127s2015 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2015.033 $2 doi
- 024 7_
- $a 10.5507/bp.2015.033 $2 doi
- 035 __
- $a (PubMed)26175050
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Hušáková, Markéta $u Institute of Rheumatology, Prague, Czech Republic $7 xx0143346
- 245 10
- $a Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris / $c M. Husakova, J. Lippert, J. Stolfa, L. Sedova, P. Arenberger, Z. Lacinova, K. Pavelka
- 520 9_
- $a BACKGROUND AND AIMS: Psoriasis vulgaris (PV) is complicated in up to 40% patients by the inflammatory joint disease psoriatic arthritis (PsA). Neither the aetiology of the arthritis nor specific laboratory markers for its disease activity have been clearly elucidated. Prolactin (PRL) acts as a cytokine with immunomodulatory functions and plays a role in skin and joint biology. The results on PRL however as a marker are unclear. The aim of this study was to confirm whether serum PRL levels reflect systemic complications of PV, like inflammatory joint disease and/or can serve as a marker of disease activity in both cases. METHODS: A total of 70 patients with PV without arthritis and 40 patients suffering from PsA were included. In all patients, we determined skin disease activity according to the PASI index and in PsA, active disease assessed as swollen or tender joints. The control group included 27 age and sex matched healthy individuals. The concentration of PRL in the serum was measured by immunoradiometric assays. RESULTS: The PRL serum levels were significantly increased in PsA patients (299.2±28.29 mIU/L) compared to PV only patients (201.4.2±11.72 mIU/L), P = 0.0003 and healthy individuals (198.2±15.31 mIU/L), P = 0.007. The serum PRL levels in PsA with active disease 336.8±42.50 (mIU/L) were higher than in PV and controls, P < 0.0001 and P = 0.002 respectively. In PV only patients, there was no correlation between PASI and PRL levels. CONCLUSION: Our results showed that PRL serum levels are a marker of active arthritis in PsA and reflects systemic complication rather than local skin activity.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a psoriatická artritida $x diagnóza $7 D015535
- 650 _2
- $a biologické markery $x metabolismus $7 D015415
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoradiometrická analýza $7 D015592
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prolaktin $x metabolismus $7 D011388
- 650 _2
- $a psoriáza $x diagnóza $7 D011565
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lippert, Jan, $u Department of Dermatology, Stadt. Klinikum Gorlitz, Gorlitz, Germany $d 1977- $7 xx0121771
- 700 1_
- $a Štolfa, Jiří, $u Institute of Rheumatology, Prague, Czech Republic $d 1944- $7 mzk2007386022
- 700 1_
- $a Šedová, Liliana $u Institute of Rheumatology, Prague, Czech Republic $7 xx0054446
- 700 1_
- $a Arenberger, Petr, $u The Clinic of Dermatology and Venereology, 3rd Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague $d 1958- $7 nlk19990072992
- 700 1_
- $a Lacinová, Zdeňka $u 3rd Department of Internal Medicine - Department of Endocrinology and Metabolism, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague $7 xx0062138
- 700 1_
- $a Pavelka, Karel, $u Institute of Rheumatology, Prague, Czech Republic $d 1954- $7 jn99240000847
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 159, č. 4 (2015), s. 562-568
- 856 41
- $u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20170127 $b ABA008
- 991 __
- $a 20170307133011 $b ABA008
- 999 __
- $a ok $b bmc $g 1192536 $s 964937
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 159 $c 4 $d 562-568 $e 20150710 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20170127